GUIDE FOR HEALTHCARE PROFESSIONALS

Information on the risks of Valproate (Epilim) use in girls (of any age), women of childbearing potential and pregnant women.

Read this booklet carefully before prescribing valproate to girls (of any age) and women of childbearing potential.

This Guide is a risk minimisation measure part of prevent – the valproate pregnancy prevention programme, aimed at minimising pregnancy exposure during treatment with valproate.

It is recommended that pregnant women taking antiepileptic drugs in general, and valproate in particular, are enrolled in the Irish Epilepsy and Pregnancy Register (www.epilepsypregnancyregister.ie). This should be done as early as possible in the pregnancy, before the outcome is known.

The information in this Guide has been approved by the HPRA
PURPOSE OF THIS GUIDE

This Guide for healthcare professionals (HCPs) is an educational material, part of prevent – the valproate pregnancy prevention programme, which is directed at both healthcare professionals and patients.

Its objective is to provide information about the teratogenic risks associated with the use of valproate during pregnancy, the actions necessary to minimise the risks to your patients, and to ensure your patient has an adequate level of understanding of the risk.

It provides up-to-date information about the risks of congenital malformations and neurodevelopmental disorders in children exposed to valproate during pregnancy.

The nature of the risks for children exposed to valproate during pregnancy are the same irrespective of the indication for which valproate has been prescribed. Therefore, the risk minimisation measures described in this Guide apply to the use of valproate regardless of the indication.

HCPs targeted by this Guide include, but are not limited to: specialists involved in the treatment of epilepsy or bipolar disorder, general practitioners and pharmacists.

The valproate educational materials developed specifically for girls (of any age) and women of childbearing potential treated with valproate comprise:

- The Patient Guide
- The Annual Risk Acknowledgment Form, and
- The Patient Card.

Use this Guide together with the Patient Guide.
1. Conditions of valproate prescription: prevent – the pregnancy prevention programme

Valproate is an effective treatment for epilepsy and bipolar disorder.

In girls and women of childbearing potential* valproate must be initiated and supervised by a specialist experienced in the management of epilepsy or bipolar disorder.

Valproate should not be used in girls and women of childbearing potential unless other treatments are ineffective or not tolerated.

Valproate may be initiated in girls and women of childbearing potential only if the conditions of prevent – the valproate pregnancy prevention programme (outlined below) are fulfilled.

How do I implement the prevent programme?

Specialists
- Discuss the risks with the patient (or parent/caregiver/responsible person)
- Exclude pregnancy in women of childbearing potential (by serum pregnancy test) before the first prescription is issued
- Arrange for highly effective** contraception for women of childbearing potential before the first prescription is issued
- Complete the Annual Risk Acknowledgment Form with patient (or parent/caregiver/responsible person); give them a copy and send a copy to the GP
- See the patient urgently if referred back in case of unplanned pregnancy or if she wants to plan a pregnancy
- Provide a copy of the Patient Guide to the patient (or parent/caregiver/responsible person)

General practitioners
- Ensure continuous use of highly effective contraception in all women of childbearing potential (consider the need for pregnancy testing if not a highly effective method)
- Check that all patients have an up to date, signed, Annual Acknowledgment of Risk Form each time a repeat prescription is issued
- Ensure the patient is referred back to the specialist for review, annually
- Refer back to the specialist urgently in case of unplanned pregnancy or where a patient wants to plan a pregnancy.
These conditions also concern women who are not currently sexually active unless the prescriber considers that there are compelling reasons to indicate that there is no risk of pregnancy.

Individual circumstances should be evaluated in each case, involving the patient in the discussion, to guarantee her engagement, discuss therapeutic options and ensure her understanding of the risks and the measures needed to minimise the risks.

**Highly effective contraception** is considered for regulatory purposes to be those user independent methods such as the long acting reversible contraceptives (LARC), copper intrauterine device (Cu-IUD), levonorgestrel intrauterine system (LNG-IUS) and progestogen-only implant (IMP) and female sterilisation, all of which have a failure rate of less than 1% with typical use. The progesterone-only injectable is reported to have a typical use failure rate of 6 pregnancies per 100 women per year of typical use compared to 0.2 pregnancies with perfect use (thought to be due to the 3 monthly requirement for re-injection and lack of compliance with this).

User dependent methods such as the condom, cap, diaphragm, combined oral contraceptive pill (COC) or progestogen-only contraceptive pill (POP) and fertility awareness based methods are not considered highly effective since the typical use incorporates user failure risks.

For children or for patients without the capacity to make an informed decision, provide the information and advice on highly effective methods of contraception and on the use of valproate during pregnancy to their parents / legal guardian / caregiver and make sure they clearly understand the content.

Please read the most up-to-date version of the Summary of Product Characteristics before prescribing valproate.

---

**2. Treatment of girls (of any age) and women of childbearing potential with valproate – actions for healthcare professionals**

**Actions for general practitioners**

Valproate is contraindicated in women of childbearing potential unless the conditions of prevent – the valproate pregnancy prevention programme are fulfilled.

**1. Existing female patients**

- Identify all women of childbearing potential on valproate
- Recall any women who may be of childbearing potential and arrange for contraception if not already using contraception
- Inform her of the known risks and ensure that she understands she must not get pregnant whilst taking valproate
- Tell her to contact you immediately if she suspects there has been a problem with her contraception or she may be pregnant
- Refer to her specialist† (unless she has seen one recently and is on prevent)
- Arrange to see each woman of childbearing potential after specialist review and ensure she is on prevent, i.e. ensure that:
  - she has the Patient Guide and has a copy of the Annual Risk Acknowledgment Form signed by the specialist
  - you file a copy of the signed Annual Risk Acknowledgment Form in her medical records
  - she is using contraception and understands the need to comply with contraception throughout treatment and undergo pregnancy testing when required – e.g. if there is any reason to suggest lack of compliance or effectiveness of contraception
  - Remind her that she will need to see her specialist at least every year while taking valproate medicines and arrange for referral as necessary.

**†Specialist prescriber is defined as a consultant psychiatrist or a consultant neurologist who regularly manages bipolar disorder or complex epilepsy.**
2. New female patient – women of childbearing potential
   • Refer her to the relevant specialist† for diagnosis and to initiate treatment if appropriate
   • Arrange to see each woman of childbearing potential after specialist review and ensure she is on prevent, i.e. ensure that:
     • she has the Patient Guide and has a copy of the Annual Risk Acknowledgment Form signed by the specialist
     • you file a copy of the signed Annual Risk Acknowledgment Form in her medical records
     • she is using contraception and understands the need to comply with contraception throughout treatment and undergo pregnancy testing when required – e.g. if there is any reason to suggest lack of compliance or effectiveness of contraception
   • Remind her that she will need to see her specialist at least every year while taking valproate medicines and arrange for referral as necessary
   • Tell her to contact you immediately if she suspects there has been a problem with her contraception or she may be pregnant.

3. Women of childbearing potential who are planning to become pregnant
   • Inform her not to stop contraception or valproate until told to by her specialist
   • Refer to the specialist who is managing her condition.

4. Patient with unplanned pregnancy
   • Inform her not to stop valproate
   • Refer her to a specialist and ask for her to be seen urgently (within days)
   • It is recommended that pregnant women taking valproate are enrolled in the Irish Epilepsy and Pregnancy Register (www.epilepsypregnancyregister.ie).

Actions for specialist prescribers

Valproate is contraindicated in women of childbearing potential unless the conditions of prevent – the valproate pregnancy prevention programme are fulfilled.

1. Existing female patients
   • Review women who may be of childbearing potential
   • Continue treatment with valproate only if other treatments are ineffective or not tolerated and pregnancy is excluded by means of a negative pregnancy test
   • Discuss the need for her to be on the prevent programme if she is to continue taking valproate:
     • Ensure she understands the risks to the unborn child of using valproate during pregnancy and provide the Patient Guide
     • Ensure she understands the need to comply with contraception throughout treatment and undergo pregnancy testing when required – e.g. if there is any reason to suggest lack of compliance or effectiveness of contraception
     • Complete and sign the Annual Risk Acknowledgment Form (at every annual visit); give a copy to her and send one to her GP
     • Refer for contraception services as needed
     • Ensure that you invite all women on prevent for an annual review.

2. New female patient – women of childbearing potential
   • Start treatment with valproate only if other treatments are ineffective or not tolerated and pregnancy is excluded by means of a negative pregnancy test
   • Assess potential for pregnancy and if necessary discuss the need for her to be on the prevent programme if she is to take valproate:
     • Ensure she understands the risks of valproate in pregnancy
     • Switch valproate to another therapeutic option
     • Tell her not to stop contraception until the switch is achieved and she is no longer taking valproate
     • If switching is not possible refer for counselling about the risks.
   • Ensure that you invite all women on prevent for an annual review

3. Women of childbearing potential planning to become pregnant
   • Ensure she understands the risks of valproate in pregnancy
   • Switch valproate to another therapeutic option
   • Tell her not to stop contraception until the switch is achieved and she is no longer taking valproate
   • If switching is not possible refer for counselling about the risks.

†Specialist prescriber is defined as a consultant psychiatrist or a consultant neurologist who regularly manages bipolar disorder or complex epilepsy.
4. Patients with an unplanned pregnancy
   - Women presenting with an unplanned pregnancy should have their treatment switched
   - Women with epilepsy who have to continue treatment in pregnancy (i.e. if switching to an alternative treatment is not possible) should be referred to an obstetrician
   - It is recommended that pregnant women taking valproate are enrolled in the Irish Epilepsy and Pregnancy Register (www.epilepsypregnancyregister.ie).

Actions for pharmacists
   - Ensure the Patient Card is provided every time valproate is dispensed
   - Remind patients of the risks in pregnancy and the need for highly effective contraception
   - Remind patients of the need for annual specialist review
   - Ensure the patient has received the Patient Guide
   - Dispense valproate in the original package with an outer warning. Dispensing outside of original packaging should be avoided. In situations where this cannot be avoided, always provide a copy of the package leaflet and add a sticker with the warning to the outer packaging
   - If a woman of childbearing potential reports that she is not taking highly effective contraception, refer them to their GP (including by contacting the GP if necessary).

3. Switching or discontinuing valproate

Patients with bipolar disorder
Valproate is contraindicated in pregnancy.
Valproate is contraindicated in women of childbearing potential unless the conditions of prevent – the valproate pregnancy prevention programme are fulfilled (see section 1 in this Guide).

If a woman is planning to become pregnant, the prescriber must switch the patient to another treatment. Switching should be achieved prior to conception and before contraception is discontinued.

If a woman becomes pregnant, treatment with valproate must be switched and discontinued to another treatment.

Patients with epilepsy
Valproate is contraindicated in pregnancy unless there is no suitable alternative treatment.
Valproate is contraindicated in women of childbearing potential unless the conditions of prevent – the valproate pregnancy prevention programme are fulfilled (see section 1 in this Guide).

If a woman is planning to become pregnant, a specialist experienced in the management of epilepsy must reassess valproate therapy and consider alternative treatment options. Every effort should be made to switch to appropriate alternative treatment prior to conception and before contraception is discontinued.

If a woman becomes pregnant on valproate, she must be immediately referred to a specialist to consider alternative treatment options.
If, despite the known risks of valproate in pregnancy and after careful consideration of alternative treatment, in exceptional circumstances a pregnant woman must receive valproate for epilepsy it is recommended to:

- Use the lowest effective dose and divide the daily dose of valproate into several small doses to be taken throughout the day
- The use of a prolonged release formulation may be preferable to other treatment formulations in order to avoid high peak plasma concentrations
- All patients with a valproate exposed pregnancy and their partners should be referred to a specialist experienced in prenatal medicine
- Enrol pregnant women taking valproate in the Irish Epilepsy and Pregnancy Register (www.epilepsypregnancyregister.ie).

4. Information on congenital malformations and on developmental disorders

Valproate contains valproic acid, an active ingredient with known teratogenic effects which may result in congenital malformations.

1. Congenital malformations

Data derived from a meta-analysis (including registries and cohort studies) have shown that 10.73% of children of epileptic women exposed to valproate monotherapy during pregnancy suffer from congenital malformations (95% confidence interval: 8.16–13.29%). This represents a greater risk of major malformations than for the general population, for whom the risk is equal to about 2–3%. Available data show that the risk is dose-dependent. The risk is greatest at higher doses. A threshold dose below which no risk exists cannot be established based on available data.

The most common types of malformations include neural tube defects, facial dysmorphism, cleft lip and palate, craniosenosis, cardiac, renal and urogenital defects, limb defects (including bilateral aplasia of the radius), and multiple anomalies involving various body systems.

Folate supplementation before the pregnancy may decrease the risk of neural tube defects which may occur in all pregnancies. However the available evidence does not suggest it prevents the birth defects or malformations due to valproate exposure.

2. Developmental disorders

Exposure to valproate in utero can have adverse effects on mental and physical development of the exposed children. The risk seems to be dose-dependent but a threshold dose below which no risk exists cannot be established based on available data. The exact gestational period of risk for these effects is uncertain and the possibility of a risk regardless of when during the pregnancy exposure occurs cannot be excluded.

Studies in preschool children show that 30–40% of children with a history of valproate exposure in utero experience delays in their early development such as talking and walking later, lower intellectual abilities, poor language skills (speaking and understanding) and memory problems.
Intelligence quotient (IQ) measured in school aged children (age 6 years old) with a history of valproate exposure \textit{in utero} was on average 7–10 points lower than children exposed to other antiepileptic drugs. Although the role of confounding factors cannot be ruled out, there is evidence in children exposed to valproate that the risk of intellectual impairment may be independent from maternal IQ.

There are limited data on the long term outcomes. Available data show that children with a history of valproate exposure \textit{in utero} are at increased risk of autistic spectrum disorder (an approximately three-fold increased risk) and childhood autism (an approximately five-fold increased risk) compared with the general study population.

Limited data suggest that children with a history of valproate exposure \textit{in utero} may be more likely to develop symptoms of attention deficit/hyperactivity disorder (ADHD).

REFERENCES

For further copies of this information booklet please contact Sanofi medical information department on 01-4035600 or email IEmedinfo@sanofi.com

Information about valproate use can also be found online at www.hpra.ie. Enter “Epilim” or “valproate” in the search box and then click on “EdM” next to any of the medicines that appear.

Adverse event reporting

This medicinal product is subject to additional monitoring. Adverse events should be reported. Reporting forms and information can be found at www.hpra.ie

Adverse events should also be reported to the Sanofi drug safety department on 01-4035600.